[go: up one dir, main page]

TR199801816T2 - Kusmaya karsi ve merkez sinir sistemi bozukluklarinin tedavisinde optikçe saf (+) Norsisaprid kullanimi. - Google Patents

Kusmaya karsi ve merkez sinir sistemi bozukluklarinin tedavisinde optikçe saf (+) Norsisaprid kullanimi.

Info

Publication number
TR199801816T2
TR199801816T2 TR1998/01816T TR9801816T TR199801816T2 TR 199801816 T2 TR199801816 T2 TR 199801816T2 TR 1998/01816 T TR1998/01816 T TR 1998/01816T TR 9801816 T TR9801816 T TR 9801816T TR 199801816 T2 TR199801816 T2 TR 199801816T2
Authority
TR
Turkey
Prior art keywords
nervous system
central nervous
norcisapride
treatment
optically pure
Prior art date
Application number
TR1998/01816T
Other languages
English (en)
Inventor
R. Mccullough John
P. Jerussi Thomas
Original Assignee
Sepracor Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc. filed Critical Sepracor Inc.
Publication of TR199801816T2 publication Critical patent/TR199801816T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Bu bulus, terkipler ve bunlarin merkezi sinir sistemi (MSS) bozukluklarini, kusmayi ve mide-bagirsak hareketi islev bozukluklarini tedavi etmek için kullanimi ile ilgilidir.Bu bulus baska bir yönünde, sisapridin metabolitleri ve bu gibi metabolitlerin optik izomerleri ile ilgilidir.
TR1998/01816T 1996-07-19 1997-07-02 Kusmaya karsi ve merkez sinir sistemi bozukluklarinin tedavisinde optikçe saf (+) Norsisaprid kullanimi. TR199801816T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/684,753 US5739151A (en) 1996-07-19 1996-07-19 Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride

Publications (1)

Publication Number Publication Date
TR199801816T2 true TR199801816T2 (tr) 2000-10-23

Family

ID=24749413

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1998/01816T TR199801816T2 (tr) 1996-07-19 1997-07-02 Kusmaya karsi ve merkez sinir sistemi bozukluklarinin tedavisinde optikçe saf (+) Norsisaprid kullanimi.

Country Status (25)

Country Link
US (3) US5739151A (tr)
EP (1) EP0896539B1 (tr)
JP (1) JP3097697B2 (tr)
KR (4) KR100399808B1 (tr)
CN (1) CN1215992A (tr)
AT (1) ATE197762T1 (tr)
AU (1) AU3592097A (tr)
BG (1) BG63190B1 (tr)
BR (1) BR9708287A (tr)
CA (1) CA2245768C (tr)
CZ (1) CZ293478B6 (tr)
DE (1) DE69703617T2 (tr)
DK (1) DK0896539T3 (tr)
ES (1) ES2152687T3 (tr)
GR (1) GR3035460T3 (tr)
HU (1) HUP9904360A3 (tr)
IL (1) IL125703A0 (tr)
IS (1) IS4820A (tr)
NO (2) NO317178B1 (tr)
NZ (1) NZ331291A (tr)
PL (1) PL189610B1 (tr)
PT (1) PT896539E (tr)
SK (1) SK282673B6 (tr)
TR (1) TR199801816T2 (tr)
WO (1) WO1998003173A1 (tr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
US6147093A (en) 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease
KR100469030B1 (ko) * 1996-10-15 2005-01-31 얀센 파마슈티카 엔.브이. 시사프라이드의 합성방법
CA2292480A1 (en) * 1997-07-11 1999-01-21 Janssen Pharmaceutica N.V. (+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders
JP2002518352A (ja) * 1998-06-15 2002-06-25 セプラコア インコーポレーテッド 無呼吸、過食症およびその他の障害を治療するための光学的に純粋な（＋）−ノルシスアプリドの使用
EP1468685A3 (en) * 1998-06-15 2004-12-15 Sepracor Inc. Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
TR200103760T2 (tr) * 1998-06-15 2002-06-21 Sepracor Inc. Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı
EP1464333A3 (en) * 1998-06-15 2004-12-15 Sepracor Inc. Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders
PL200132B1 (pl) * 1998-08-21 2008-12-31 Novartis Ag Zastosowanie 3-(5-metoksy-1H-indol-3-ilometyleno)-N-pentylokarbazyimidoamidu
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6362202B1 (en) 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6803387B1 (en) * 1999-03-19 2004-10-12 Abbott Gmbh & Co. Kg Treatment of neuropathic pain or fibromyalgia
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
EP1321142A1 (en) * 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
FR2854072B1 (fr) * 2003-04-23 2006-08-04 Centre Nat Rech Scient Vecteur pour administration par voie orale
US8138204B2 (en) * 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
PT2194053E (pt) * 2004-01-07 2013-07-08 Armetheon Inc Derivados de metoxipiperidina para utilização no tratamento de distúrbios gastrointestinais e do sistema nervoso central
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US20090170899A1 (en) * 2004-09-14 2009-07-02 Guy Debonnel Stimulators of 5-HT4 receptors and uses thereof
DK1919909T3 (da) * 2005-08-31 2013-12-02 Armetheon Inc Syntesemetoder og mellemprodukter for stereoisomere forbindelser, der er anvendelige til behandling af gastrointestinale forstyrrelser og forstyrrelser i centralnervesystemet
US20080085915A1 (en) * 2006-06-23 2008-04-10 Cyrus Becker Compounds and methods for the treatment of gastrointestinal and central nervous system disorders
KR20120107075A (ko) 2009-10-16 2012-09-28 에파이오메드 테라퓨틱스, 아이엔씨. 구토 치료
AU2012221927B2 (en) * 2011-02-25 2016-04-28 Yuhan Corporation Diaminopyrimidine derivatives and processes for the preparation thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962115A (en) * 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) * 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US5137896A (en) * 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5114714A (en) * 1990-11-29 1992-05-19 Sepracor, Inc. Methods of use and compositions of (r)-isoflurane and (r)-desflurane
US5114715A (en) * 1990-11-29 1992-05-19 Sepracor Inc. Methods of use and compositions of (s)-isoflurane and (s)-desflurane
WO1994001112A1 (en) * 1992-07-07 1994-01-20 Sepracor Inc. Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
CA2139636A1 (en) * 1992-07-07 1994-01-20 Nancy M. Gray Methods of using (+) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
JPH08512322A (ja) * 1993-07-06 1996-12-24 メルク エンド カンパニー インコーポレーテッド Ｈ▲下２▼拮抗剤−胃腸運動性の薬剤組合せ物
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride

Also Published As

Publication number Publication date
HUP9904360A2 (hu) 2000-05-28
EP0896539A1 (en) 1999-02-17
CZ293478B6 (cs) 2004-05-12
NO20041166L (no) 2004-03-19
ATE197762T1 (de) 2000-12-15
KR100399808B1 (ko) 2003-09-29
IL125703A0 (en) 1999-04-11
PL189610B1 (pl) 2005-08-31
NO317178B1 (no) 2004-09-06
WO1998003173A1 (en) 1998-01-29
BG63190B1 (bg) 2001-06-29
NO983636L (no) 1998-10-19
AU3592097A (en) 1998-02-10
CA2245768C (en) 2003-09-30
US5739151A (en) 1998-04-14
CA2245768A1 (en) 1998-01-29
EP0896539B1 (en) 2000-11-29
ES2152687T3 (es) 2001-02-01
JP3097697B2 (ja) 2000-10-10
BG102757A (en) 1999-08-31
US5877188A (en) 1999-03-02
HUP9904360A3 (en) 2001-07-30
IS4820A (is) 1998-08-10
PT896539E (pt) 2001-05-31
CZ250898A3 (cs) 1999-04-14
KR100328731B1 (ko) 2002-10-19
CN1215992A (zh) 1999-05-05
NO983636D0 (no) 1998-08-07
NZ331291A (en) 2000-06-23
KR20000064524A (ko) 2000-11-06
DK0896539T3 (da) 2001-02-19
GR3035460T3 (en) 2001-05-31
DE69703617D1 (de) 2001-01-04
KR100533237B1 (ko) 2005-12-05
SK123998A3 (en) 1999-03-12
KR100422492B1 (ko) 2004-03-11
US6114356A (en) 2000-09-05
SK282673B6 (sk) 2002-11-06
JPH11510828A (ja) 1999-09-21
KR20040007505A (ko) 2004-01-24
PL335254A1 (en) 2000-04-10
DE69703617T2 (de) 2001-04-12
BR9708287A (pt) 2000-01-18

Similar Documents

Publication Publication Date Title
TR199801816T2 (tr) Kusmaya karsi ve merkez sinir sistemi bozukluklarinin tedavisinde optikçe saf (+) Norsisaprid kullanimi.
DK0914116T3 (da) Kompositstoffer omfattende konjugater af cis-docosahexaensyre og Taxotere
DK0912535T3 (da) Konjugater af cis-docosahexaensyre og paclitaxel
TR200102029T2 (tr) 1-Heterosiklil ikameli diarilaminler.
DE69925909D1 (de) T-zell inhibierende rezeptorzusammensetzungen sowie deren verwendung
TR199801302T2 (tr) Ikame edilmis aza ve diazasikolopentan ve siklooktan bilesikleri.
FI951138A7 (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
TR199701074T1 (tr) Sinerjistik bilesimler.
TR199700993T1 (tr) 5-ikameli-3-(1,2,3,6-tetrahidropridin-4-il)- ve 3-(piperidin-4-il)-1H-indoller: yeni 5-HT1F agonistler.
UA10911C2 (uk) Біосумісhий гідрогель
DE59712873D1 (de) Halogenpyrimidinylaryl(thio)ether als pestizide
FI830708L (fi) 1,2,4-triazin- och pyrazinderivat
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
DE69919537D1 (de) Arylsubstituierte olefinische amine und ihre verwendung als cholinergische rezeptoragonisten
DE69840603D1 (de) Alpha-ketoamidhaltige multikatalytische protease inhibitoren
CY1105482T1 (el) Χρηση της αζιθρομυκινης στην τοπικη αγωγη οφθαλμικων μολυνσεων
UA32599C2 (uk) Пристрій для обробки деревини
PL341100A1 (en) Electrochromatic device protected against uv radiation
TR200103123T2 (tr) Monofluoroalkil türevleri.
YU41998A (sh) Tetrahidrobetakarbolinska jedinjenja
TR199802704T2 (tr) HIV tedavisinde Vx478, Zidovüdin, FTC ve/veya 3TC içeren kombinasyonlarin kullanimi.
TR200100921T2 (tr) Terkipler ve bunların mide-özofagus geri akım hastalığı için kullanımı
TR200001970T2 (tr) MSS bozukluklarının tedavisine mahsus triazin bileşikleri.
NO955288L (no) Skvalen-syntetase inhibitorer
DK1143917T3 (da) Antikonvulsive derivater egnet til behandling af posttraumatisk stresssygdom